Read these Data and draw your own conclusion. I believe Ach-1625 is right up there or even better:http://finance.yahoo.com/news/gilead-announces-early-sustained-virologic-090000254.html
Those studies also revealed patients are prone to relapse after stopping treatment. Facts sheet regarding Ach-3102 beat out BMS-052. Things are getting interesting when poster presentation of Achillion's second generation NS5A are made public.
Yesterday was an ambush by GILD, knowing ACHN would be presenting this weekend.